June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Spectral-domain OCT predictors of successful treatment discontinuation in patients with retinal vein occlusion and macular edema
Jaycob Avaylon; Daniella Lent-Schochet; Kiana Nava; Therlinder Lo; Kieu-Yen Luu; Steven Tran; Parisa Emami-Naeini; Ala Moshiri; Susanna S Park; Glenn Yiu
Author Affiliations & Notes
  • Jaycob Avaylon
    California Northstate University College of Medicine, Elk Grove, California, United States
  • Daniella Lent-Schochet
    Department of Ophthalmology and Vision Science, University of California Davis, Sacramento, California, United States
    Department of Ophthalmology and Vision Science, University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States
  • Kiana Nava
    University of California Davis, Davis, California, United States
  • Therlinder Lo
    Department of Ophthalmology and Vision Science, University of California Davis, Sacramento, California, United States
  • Kieu-Yen Luu
    Department of Ophthalmology and Vision Science, University of California Davis, Sacramento, California, United States
  • Steven Tran
    Department of Ophthalmology and Vision Science, University of California Davis, Sacramento, California, United States
  • Parisa Emami-Naeini
    Department of Ophthalmology and Vision Science, University of California Davis, Sacramento, California, United States
  • Ala Moshiri
    Department of Ophthalmology and Vision Science, University of California Davis, Sacramento, California, United States
  • Susanna S Park
    Department of Ophthalmology and Vision Science, University of California Davis, Sacramento, California, United States
  • Glenn Yiu
    Department of Ophthalmology and Vision Science, University of California Davis, Sacramento, California, United States
  • Footnotes
    Commercial Relationships   Jaycob Avaylon None; Daniella Lent-Schochet None; Kiana Nava None; Therlinder Lo None; Kieu-Yen Luu None; Steven Tran None; Parisa Emami-Naeini None; Ala Moshiri None; Susanna Park None; Glenn Yiu Abbvie, Alimera, Anlong, Clearside, Endogena, Genentech, Gyroscope, Intergalactic, Iridex, NGM Biopharmaceuticals, Regeneron, Thea, Topcon, Zeiss, Code C (Consultant/Contractor)
  • Footnotes
    Support  NIH R01 EY032238, NIH R34 EY031719
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3333 – F0142. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Spectral-domain OCT predictors of successful treatment discontinuation in patients with retinal vein occlusion and macular edema
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Jaycob Avaylon, Daniella Lent-Schochet, Kiana Nava, Therlinder Lo, Kieu-Yen Luu, Steven Tran, Parisa Emami-Naeini, Ala Moshiri, Susanna S Park, Glenn Yiu; Spectral-domain OCT predictors of successful treatment discontinuation in patients with retinal vein occlusion and macular edema. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3333 – F0142.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : To identify longitudinal SD-OCT biomarkers associated with successful treatment discontinuation and visual outcomes in eyes with central or branch retinal vein occlusion (RVO) and macular edema.

Methods : We retrospectively reviewed 66 eyes with treatment-naïve RVO and ME with 24-month follow-up, and assessed SD-OCT biomarkers including central subfield thickness (CST), intraretinal cyst size, number of intraretinal hyperreflective foci (HF), disorganization of retinal inner layers (DRIL), and outer retinal layer disruptions of the external limiting membrane (ELM), ellipsoid zone (EZ), or interdigitation zone (IZ) at presentation, 3 months, or 6 months after treatment initiation. We employed multivariate regression analyses to identify biomarkers associated with (1) successful treatment discontinuation for at least 6 months without fluid recurrence and (2) visual acuity (VA) at 24-months.

Results : Among 43 eyes with CRVO/HRVO and 23 with BRVO, 47% and 49% of eyes successfully stopped therapy over the 2 years, respectively, with a median time to discontinuation of 5 months (95% CI 2-8) for the CRVO/HRVO group and 5 months (95% CI 3-8) for the BRVO group. SD-OCT biomarkers including CST, cyst size, DRIL, and ELM/EZ/EZ disruptions all improved at 3 months, and remained stable at 6 months. On multivariate regression, lower CST at 6 months (P = 0.03) was associated with successful treatment discontinuation, while better BCVA at 6 months (P = 0.04) and %DRIL improvement at 3 months (P = 0.02) predicted better visual outcomes at 24 months.

Conclusions : Early anatomic response at 6 months is associated with successful treatment discontinuation of RVO with macular edema within 2 years, while early visual gains and DRIL improvements are linked to long-term visual outcomes.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept